Proximal tubular dysfunction (PTD) is believed to be common in HIV-positive individuals, with studies finding prevalence rates of 6% to over 50%.1,2 PTD is defined as a decreased ability of the proximal tubule to reabsorb small molecules filtered by the glomerulus, such as glucose, phosphorous, and low-molecular weight proteins. The current guidelines for chronic kidney disease in HIV-positive individuals describe laboratory findings supporting a diagnosis of PTD. However, because of limited information about the performance characteristics of PTD indicators and the unclear clinical significance of PTD in asymptomatic individuals, the guidelines do not recommend routine screening for PTD.3
Many studies have identified tenofovir disoproxil fumarate (TDF), a commonly prescribed nucleotide reverse transcriptase inhibitor, as a risk factor for PTD.1–9 TDF is excreted in the urine partially through tubular secretion.10,11 Accumulation of TDF within proximal tubular cells is believed to cause PTD through mitochondrial damage.6,12,13 Current guidelines recommend avoiding TDF in patients with an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73 m2 (Infectious Disease Society of America) or a creatinine clearance of <50 mL/min/1.73 m2 (United States Department of Health and Human Services).3,8
Despite the high prevalence of PTD among people with HIV, there are key gaps in our knowledge of the natural history of HIV-related and TDF-associated PTD. In particular, there are few studies assessing PTD in demographically similar HIV-negative persons, the persistence of PTD indicators over time, or the implication of PTD for subsequent GFR change.3,14–16 Using data from a cohort of HIV-positive participants, many with long treatment histories, and HIV-negative participants followed over 3 years, our objectives were to (1) assess the associations between HIV serostatus, TDF use, and PTD; (2) assess changes in the prevalence of PTD over the course of the study; and (3) assess the association between PTD at baseline and measured GFR (mGFR) trajectory. We used 3 indicators of PTD that have been proposed in guidelines and are readily available in clinical practice: phosphaturia, tubular proteinuria, and glycosuria with normoglycemia.3
Study Design and Population
The Mr. Bean study is a prospective cohort in Baltimore, MD, recruited in 2011–2012 to assess demographic, behavioral, and viral [HIV and hepatitis C virus (HCV)] factors associated with the progression of kidney and cardiovascular disease among individuals with initially normal estimated kidney function.17 We recruited HIV-positive participants from the Johns Hopkins HIV clinic and HIV-negative participants from the community in a 2:1 ratio. We recruited HIV-negative subjects through local media advertising and from a cohort of persons with a history of injection drug use, the latter to achieve comparable behavioral characteristics and HCV seropositivity rates to the HIV-positive sample.18 Inclusion criteria were age 18 years or older and eGFR ≥60 mL/min/1.73 m2 based on the Modification of Diet in Renal Disease (MDRD) equation.19 Exclusion criteria included history of radiocontrast allergy, pregnancy, diabetes mellitus, uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg), collagen vascular disease, or life-threatening comorbidity. After screening and enrollment, participants completed a baseline study visit and up to 3 annual follow-up visits. Laboratory results from this study were not routinely made available to clinicians caring for enrolled patients. The study was approved by the Johns Hopkins Medicine Institutional Review Board and participants provided written informed consent.
Data Collection and Measurements
At each study visit, we collected demographic, behavioral, clinical, and pharmacologic data by interview and medical record review, and measured blood pressure, height, and weight. Laboratory testing at each study visit included plasma concentrations of creatinine, phosphorous, CD4 cell count, and HIV RNA level (lower limit of detection of 400 copies/mL). In addition, we measured fasting urine concentrations of creatinine, albumin, protein, and phosphorus from fresh urine samples at each study visit. Plasma and urine chemistry testing was performed by the Johns Hopkins Hospital clinical laboratory with a Cobas 8000 c701 analyzer (Roche Diagnostics, Indianapolis, IN) using an enzymatic creatinase method for creatinine, spectrophotometry for phosphorus, a turbidimetric assay for protein, and an immunoturbidimetric assay for albumin. Urine glucose was assessed with a fully automated dipstick method (Aution 9 EB; Arkray, Inc., Kyoto, Japan) using a glucose oxidation reaction.
We measured GFR at each study visit using iohexol disappearance from plasma (mGFR), as has been previously described.17 HCV serostatus was determined at baseline by HCV serology with reflex to HCV RNA if seropositive. Participants with detectable HCV RNA were considered to have active hepatitis C infection.
Participants were considered “ever smokers” if they reported having smoked at least 100 cigarettes during their lifetime. Participants were considered “current smokers” if they reported active cigarette use at baseline. Time since antiretroviral therapy (ART) initiation was defined as the number of months since ART initiation, with no adjustments for possible lapses in therapy. Cumulative exposure to TDF was defined as the number of months of TDF use before start of the study, excluding lapses in TDF use.
Urine measures of kidney injury and proximal tubular function included albumin–creatinine ratio (ACR), protein–creatinine ratio (PCR), albumin–protein ratio (APR), and fractional excretion of phosphorous (FEphos). The APR was calculated as ACR/PCR, and FEphos was calculated as [(urine phosphorous concentration) × (serum creatinine concentration)/(urine creatinine concentration) × (serum phosphorous concentration)] × 100. Consistent with guidelines,20 we defined albuminuria as an ACR ≥30 mg/g and proteinuria as PCR ≥200 mg/g. Subjects who met criteria for proteinuria were further categorized as having glomerular proteinuria (APR >0.4) or tubular proteinuria (APR ≤0.4). Tubular proteinuria has been proposed as a marker of PTD, as low-molecular weight proteins (which are normally resorbed by the proximal tubule) account for a large relative share of total proteinuria compared with albumin.21,22 A recent study of biopsy-proven TDF nephrotoxicity suggested that low urine APR (ie, nonalbumin proteinuria) is a reliable feature of TDF-associated nephrotoxicity.23 We defined low serum phosphate (hypophosphatemia) as serum phosphate <2.5 mg/dL.
We defined PTD as the presence of at least one the following3: nondiabetic glycosuria (>100 mg/dL by semiquantitative dipstick) in the presence of normoglycemia (serum glucose <126 mg/dL), phosphaturia, defined as FEphos >18%, 1,24 or the presence of tubular proteinuria. Data from study visits at which urine samples were abnormally dilute (creatinine concentration <10 mg/dL) or where more than one of the 3 PTD criteria could not be assessed were excluded.
We compared baseline demographic, behavioral, and laboratory characteristics in 4 groups: (1) HIV-positive participants taking TDF-based ART, (2) HIV-positive participants taking TDF-sparing ART, (3) HIV-positive participants not taking ART, and (4) HIV-negative participants. We used Fisher exact tests and Kruskal–Wallis tests for categorical and continuous variables, respectively. We used a logistic regression to assess the association between cumulative ART/TDF exposure and baseline PTD. The duration of ART and TDF exposure was natural log-transformed because of the wide range of cumulative exposure.
We used univariate and multivariate generalized estimating equation logistic regression with an exchangeable correlation structure to identify factors associated with PTD across all visits. The time-fixed covariates were HIV-infection status, sex, race, baseline smoking status, history of hypertension, history of cardiovascular disease, and active HCV infection. The time-varying covariates were age, body mass index (BMI), plasma creatinine, systolic blood pressure, diastolic blood pressure, glycosylated hemoglobin, use of ART and TDF among HIV-positive subjects, use of nonsteroidal anti-inflammatory drugs (NSAID), and use of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB). Covariates for the multivariate model were selected in a backward stepwise manner; covariates with a P-value of <0.05 were retained in the final model and tested for interactions. We also assessed an alternate categorization scheme for participants: (1) HIV-negative, (2) HIV-positive not on ART, (3) HIV-positive on ART with a detectable viral load, and (4) HIV-positive on ART with an undetectable viral load. In this case, use of ART and viral suppression status was time-varying.
We used linear mixed effects models to assess the association between baseline PTD and mGFR slope, stratified by HIV serostatus. In multivariate slope models, we controlled for age, race, sex, and viral suppression. STATA 14.1 (STATA Corp., College Station, TX) was used for all analyses.
A total of 292 participants (192 HIV-positive and 100 HIV-negative) were included in the study. These participants completed a total of 1030 study visits, with individuals completing a median (25th percentile, 75th percentile) of 4 (3, 4) study visits. We excluded 8 study visits because of abnormally dilute urine or more than 1 missing measure of PTD, leaving 1022 visits in the analysis of risk factors for PTD. Of the 1022 total study visits, 952 had valid mGFR measurements for the mGFR slope analysis.
Baseline Clinical Characteristics
The HIV-status/ART groups were similar in age, BMI, race, and smoking status (Table 1). The HIV-positive groups had higher proportions of women, were more likely to have active HCV infection, and were more likely to be taking an ACEi or ARB at baseline. However, there was no significant difference in hypertension or hemoglobin A1c between the groups.
HIV-positive individuals not taking ART were significantly more likely than other HIV-positive participants to have a detectable viral load. HIV-positive individuals taking ART (with or without TDF) had lower CD4 nadirs than HIV-positive participants not taking ART. HIV-positive participants taking ART with and without TDF had similar durations of ART use before the beginning of the study. Seven of the 17 subjects not on ART at baseline were ART-naive; the other 10 had previous ART exposure. As expected, cumulative exposure to TDF was highest in HIV-positive subjects receiving TDF at baseline.
Baseline plasma creatinine was statistically significantly different between the groups, although the differences were not clinically significant, with the median baseline plasma creatinine in all groups between 0.9 and 1.0 mg/dL. Baseline mGFR was lowest in participants on TDF-sparing ART (80 mL/min/1.73 m2), and highest in HIV-negative participants (96 mL/min/1.73 m2). The prevalence of hypophosphatemia was similar among the groups at baseline (Table 1) and during follow-up (data not shown). Compared with HIV-negative participants, the prevalence of PTD at baseline was higher in the HIV-positive groups, particularly the group not taking ART.
Among HIV-positive participants, cumulative exposure to TDF was not significantly associated with baseline PTD, in either the unadjusted analysis [odds ratio (OR) 0.97 per 1 loge increase in exposure time (months), 95% confidence interval (CI): 0.78 to 1.20] or when adjusting for time since ART initiation [adjusted OR (aOR) 1.11 per 1 loge increase in TDF exposure time, 95% CI: 0.85 to 1.44].
Patterns and Prevalence of PTD
Table 2 shows the frequencies for different patterns of PTD components among those with PTD at baseline. Tubular proteinuria was the most common PTD criterion detected, followed by FEphos >0.18. Tubular proteinuria and phosphaturia were poorly correlated, and did not co-occur in individual participants any more frequently than would be expected by chance (Kappa 0.05, 95% CI: −0.06 to 0.17). Only a single participant had nondiabetic glycosuria at baseline, and this individual also had tubular proteinuria. There were only 24 visits (of 1022 visits) by 20 different participants (of 292 subjects) at which more than one criterion for PTD was met.
Table 3 shows the prevalence of PTD over time according to the baseline HIV-serostatus/ART groups. Group differences in PTD were significantly different at baseline and the 24-month visit. One hundred thirteen participants (39%) had a change in their PTD status over the course of the study. Among subjects with at least 2 visits, 49 of 55 (89%) with PTD at baseline had at least 1 subsequent visit without PTD, and 65 of 217 (30%) without PTD at baseline had at least 1 subsequent visit with PTD.
Association of Clinical Factors With PTD
Table 4 shows the associations of clinical factors with PTD in a repeated measures analysis. Compared with HIV-negative individuals in the unadjusted analysis, all HIV-positive groups had significantly higher odds of PTD, with subjects who were not on ART having the highest odds (OR 4.67; 95% CI: 2.37 to 9.18). There were no significant associations of age, smoking status, history of cardiovascular disease, systolic/diastolic blood pressure, hemoglobin A1c, nonsteroidal anti-inflammatory drug use, or ACEi/ARB use with PTD.
Compared with HIV-negative subjects, a significant association between HIV/ART status and PTD remained only for HIV-positive subjects not taking ART (OR 3.33; 95% CI: 1.65 to 6.71) in the adjusted analysis. In addition, among HIV-positive individuals, those not taking ART were significantly more likely to have PTD than participants on TDF-based or TDF-sparing ART (OR 2.25; 95% CI: 1.22 to 4.15 and OR 2.40; 95% CI: 1.21 to 4.77, respectively). Among ART-treated individuals, use of tenofovir was not significantly associated with PTD in the adjusted analysis (OR 1.07; 95% CI: 0.66 to 1.71). Other factors associated with PTD in the adjusted analysis were female sex, white race, lower BMI, hypertension, active HCV infection, and higher plasma creatinine. The above analysis was repeated excluding HIV-positive participants who had ever received TDF from the TDF-sparing group, with no substantial changes in the results of the adjusted analysis (Appendix I, https://links.lww.com/QAI/A971).
In a supplementary analysis, in which participants were categorized by HIV status, ART use, and viral suppression, HIV-positive individuals not on ART [reference HIV-negative participants; aOR 3.48, 95% CI: 1.73 to 6.99] and HIV-positive individuals on ART with a detectable viral load (aOR 2.61, 95% CI: 1.38 to 4.92) had similar odds of PTD (Supplemental Digital Content, Appendix II, https://links.lww.com/QAI/A971). The odds of PTD for HIV-positive individuals on ART with an undetectable viral load were similar to that of HIV-negative participants (aOR 1.30, 95% CI: 0.80 to 2.08).
In an additional supplemental analysis restricted to HIV-positive participants, there was both an unadjusted (OR 2.01; 95% CI: 1.30 to 3.10) and an adjusted (OR 1.81, 95% CI: 1.10 to 3.00) association between a detectable viral load and PTD (Appendix III, https://links.lww.com/QAI/A971). Logarithmically transformed CD4 count was negatively associated with PTD in the unadjusted model (OR 0.71, 95% CI: 0.56 to 0.89), but did not reach statistical significance in the adjusted model (OR 0.78, 95% CI: 0.61 to 1.01).
Association of PTD With mGFR Slope
Among HIV-positive participants with and without PTD at baseline, the mGFR slopes were −2.96 and −1.31 mL/min/1.73 m2 per year, respectively (P = 0.084 for difference between slopes). In a model adjusting for age, sex, race, and viral suppression, the difference in mGFR slopes between HIV-positive participants with and without PTD was −1.58 mL/min/1.73 m2 per year (95% CI: −3.56 to 0.40, P = 0.12). Similarly, there was no significant difference in mGFR slopes between HIV-negative participants with and without baseline PTD (difference in slopes 0.67 mL/min/1.73 m2 per year; 95% CI: −3.00 to 4.33; P = 0.72).
Our first objective was to assess the associations of HIV status and TDF use with PTD, characterized by recommended measures of proximal tubular function that are widely available in clinical practice. Compared with HIV-negative participants, HIV-positive persons that were not taking ART were at over 3-fold the odds of having PTD, whereas those taking ART were not at significantly increased risk of PTD. Among HIV-positive individuals, there were no significant associations between current or cumulative TDF exposure and PTD. Other factors independently associated with an increased risk of PTD included low BMI, female sex, white race, active HCV infection, and higher plasma creatinine. Our second objective was to assess changes in the prevalence of PTD over the course of the study. We found that 39% of subjects had a change in PTD status over the 3 years of this study. More than 80% of participants with PTD at baseline had at least 1 follow-up visit with no PTD. Our third objective was to assess the association between PTD at baseline and mGFR trajectory. We found that PTD at baseline was not significantly associated with mGFR slope in HIV-positive or -negative subjects.
Previous studies have yielded mixed findings regarding whether TDF is a risk factor for PTD.1,2,4,7,15,16,25,26 A review noted that most studies finding an association between TDF and PTD were case–control or retrospective cohort studies, whereas randomized-controlled trials have not typically found differences in adverse kidney events in TDF recipients compared with those treated with alternative agents.6 However, recent trials comparing tenofovir alafenamide with TDF-based therapy have reported higher levels of urine retinol-binding protein and β2-microglobulin (alternative PTD markers) in the latter group, although the clinical implications of this are unknown.27,28 Our results, suggest that poorly controlled HIV may be a stronger risk factor for PTD than TDF in a nondiabetic population with long HIV treatment histories, but without clinically decreased kidney function. Consistent with this, increased levels of urine β2-microglobulin have been observed in patients with advanced HIV before the use of TDF.29
We also found higher rates of PTD in participants with low BMI, female sex, white race, active HCV infection, and higher plasma creatinine. Low BMI is a commonly reported risk factor for PTD in HIV, although this association has generally been attributed to increased TDF exposure in smaller individuals.6,25,30 Fewer studies have looked at associations between gender, race, and PTD. In particular, many cohorts used to study PTD have been predominantly male or of a single ethnicity.4,9,15,26,30 Although HCV serostatus has been included in many analyses, results have been mixed regarding whether HCV infection is an independent risk factor for PTD.1,9,25,26 Of note, female sex and HCV are risk factors for the development of reduced GFR in HIV-infected persons.3 However, although we found higher rates of PTD in whites, HIV-positive whites are at lower risk of progressive impairment in GFR compared with African Americans.3 Thus, our results highlight potential parallels, and 1 difference, between risk factors for PTD and risk factors for CKD in HIV.
In follow-up visits over 36 months, we found surprising variability in the presence or absence of PTD laboratory indicators. Over one-third (39%) of participants had a change in their PTD status over the 3 years of the study; 89% of subjects with PTD at baseline had at least 1 subsequent visit without PTD. Moreover, despite the increased risk of PTD in HIV-positive individuals, 34% of HIV-negative subjects had PTD detected at least once. There is little published on the variability of PTD indicators over time. However, our findings suggest that routine screening for PTD with the clinically available indicators we studied in HIV-infected patients may be insufficiently reliable to guide clinical management.
The relationship between PTD and GFR trajectory in patients with HIV is unclear.4,9,15 Although we found that PTD was associated with lower GFR (or higher serum creatinine) at baseline, we found no association between baseline PTD and subsequent mGFR slope over 3 years. By contrast, Kinai and Hanabusa4 found that higher levels of urine β2-microglobulin were associated with greater declines in eGFR among HIV-positive subjects on TDF. Ando et al9 showed that HIV-positive patients with evidence of baseline tubular damage were more likely than patients without baseline tubular damage to have a decline in their eGFR at 1 year. Our findings suggest that PTD (defined by the indicators we used) may be correlated with decreased kidney function, but it remains unclear whether PTD is predictive of future GFR decline.
The strengths of our study include prospective 3-year follow-up of well-characterized, demographically similar HIV-positive and HIV-negative participants. As data obtained for the study were not routinely shared with treating clinicians, these data were unlikely to have affected treatment decisions. Limitations include potential treatment selection bias, particularly as many patients had long treatment histories at the beginning of the study; absence of data on bone mineral density (a potential complication of PTD); and limited generalizability, as the cohort was predominantly African American. Finally, we characterized PTD according to readily available markers in clinical practice (glycosuria, tubular proteinuria, and FEphos). Other studies have included alternative PTD markers, such as fractional excretion of uric acid, β2-microglobulin, retinol-binding protein, neutrophil gelatinase–associated lipocalin, and others, which limits the ability to make cross-study comparisons.4,9,15,27,25
In conclusion, we found a higher prevalence of PTD in HIV-positive than in HIV-negative individuals. Among HIV-positive participants, uncontrolled viremia was the strongest correlate of PTD, although TDF use was not significantly associated with PTD. There was striking within-subject variability in the presence of PTD indicators over time, and the 2 most common indicators (tubular proteinuria and phosphaturia) occurred independently of one another. We found similarities between CKD and PTD risk factors, but no association between baseline PTD and GFR trajectory. Our results highlight the need for a consensus definition of PTD and further studies examining the association between HIV viremia, PTD, and GFR over time, in both HIV-positive and HIV-negative populations.
1. Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–696.
2. Hall AM, Edwards SG, Lapsley M, et al. Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis. Am J Kidney Dis. 2009;54:1034–1042.
3. Lucas GM, Ross MJ, Stock PG, et al. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2014;59:e96–e138.
4. Kinai E, Hanabusa H. Progressive renal tubular dysfunction associated with long-term use of tenofovir DF. AIDS Res Hum Retroviruses. 2009;25:387–394.
5. Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14:179–187.
6. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? J Am Soc Nephrol. 2013;24:1519–1527.
7. Dauchy F, Lawson-Ayayi S, de La Faille R, et al. Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy. Kidney Int. 2011;80:302–309.
8. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. Available at http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
9. Ando M, Yanagisawa N, Ajisawa A, et al. Kidney tubular damage in the absence of glomerular defects in HIV-infected patients on highly active antiretroviral therapy. Nephrol Dial Transpl. 2011;26:3224–3229.
10. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics. 2009;10:1675–1685.
11. Ray AS, Cihlar T, Robinson KL, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297–3304.
12. Herlitz LC, Mohan S, Stokes MB, et al. Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int. 2010;78:1171–1177.
13. Ramamoorthy H, Abraham P, Isaac B. Mitochondrial dysfunction and electron transport chain complex defect in a rat model of tenofovir disoproxil fumarate nephrotoxicity. J Biochem Mol Toxicol. 2014;28:246–255.
14. Hall AM, Hendry BM, Nitsch D, et al. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis. 2011;57:773–780.
15. Casado JL, Del Rey JM, Banon S, et al. Changes in kidney function and in the rate of tubular dysfunction after tenofovir withdrawal or continuation in HIV-infected patients. J Acquir Immune Defic Syndr. 2016;72:416–422.
16. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2010;55:49–57.
17. Bhasin B, Lau B, Atta MG, et al. HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate
equations based on creatinine and cystatin C. PLoS One. 2013;8:e82028.
18. Vlahov D, Anthony JC, Munoz A, et al. The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr. 1991;109:75–100.
19. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate
from serum creatinine: a new prediction equation. Ann Intern Med. 1999;130:461–470.
20. Levin A, Stevens P, Bilous R, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:e150.
21. Samarawickrama A, Cai M, Smith E, et al. Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria. HIV Med. 2012;13:526–532.
22. Smith ER, Cai MM, McMahon LP, et al. The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients. Nephrol Dial Transpl. 2012;27:1534–1541.
23. Sise ME, Hirsch JS, Canetta PA, et al. Nonalbumin proteinuria predominates in biopsy-proven tenofovir nephrotoxicity. AIDS. 2015;29:941–946.
24. Rodriguez-Novoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108–e116.
25. Oboho I, Abraham AG, Benning L, et al. Tenofovir use and urinary biomarkers among HIV-infected women in the women's interagency HIV study (WIHS). J Acquir Immune Defic Syndr. 2013;62:388–395.
26. Reynes J, Cournil A, Peyriere H, et al. Tubular and glomerular proteinuria in HIV-infected adults with estimated glomerular filtration rate
≥60 mL/min per 1.73 m2
. AIDS. 2013;27:1295–1302.
27. Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015;385:2606–2615.
28. Gallant JE, Daar ES, Raffi F, et al. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial. Lancet HIV. 2016;3:e158–e165.
29. Kabanda A, Vandercam B, Bernard A, et al. Low molecular weight proteinuria in human immunodeficiency virus-infected patients. Am J Kidney Dis. 1996;27:803–808.
30. Gatanaga H, Tachikawa N, Kikuchi Y, et al. Urinary β 2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2006;22:744–748.